EN 101

Drug Profile

EN 101

Alternative Names: EN-101; Monarsen

Latest Information Update: 23 Apr 2011

Price : $50

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Amarin Corporation
  • Class Oligodeoxyribonucleotides
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes - Amyotrophic lateral sclerosis; Inflammatory bowel diseases; Myasthenia gravis

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Inflammatory bowel diseases; Myasthenia gravis

Most Recent Events

  • 08 Nov 2010 EN 101 is available for worldwide licensing in myasthenia gravis, inflammatory bowel disease and amyotrophic lateral sclerosis as of 06 Oct 2008. http://www.amarincorp.com
  • 18 Jun 2009 Suspended - Preclinical for Amyotrophic lateral sclerosis (PO)
  • 18 Jun 2009 Suspended - Preclinical for Inflammatory bowel disease (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top